Arcus Biosciences

Arcus Biosciences

Yahoo Finance • 14 days ago

At a glance: stocks gapping down premarket

[Wall Street-Street Sign] P_Wei/E+ via Getty Images Here's a quick look at the stocks that are seeing gap-down moves before the bell on Thursday. Stock index futures were lower on Thursday as investors weighed escalating geopolitical ris... Full story

Yahoo Finance • 14 days ago

Arcus Biosciences prices $250M public offering at $17.50 per share

* Arcus Biosciences (RCUS [https://seekingalpha.com/symbol/RCUS]) stock price slipped about 6% on Thursday pre-market hours as the company priced [https://seekingalpha.com/pr/20695590-arcus-biosciences-announces-pricing-of-250-million-pu... Full story

Yahoo Finance • 14 days ago

Arcus Biosciences slides 20% on stock offering, kidney-cancer data

[Cancer Anatomy] wildpixel/iStock via Getty Images Shares of Arcus Biosciences (RCUS [https://seekingalpha.com/symbol/RCUS]), a late clinical-stage biopharmaceutical company, tumbled almost 20% on Wednesday, closing at $19.10 after fallin... Full story

Yahoo Finance • 15 days ago

William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates Coverage

CHICAGO, October 21, 2026--(BUSINESS WIRE)--William Blair today announced that Alethia Young has initiated coverage of 13 biotechnology companies, marking the next step in the firm's continued expansion of its biotech offering. Young join... Full story

Yahoo Finance • 16 days ago

Arcus Reverses Course, Surging On Its Merck-Rivaling Cancer Reveal

Arcus Biosciences touted its Merck-rivaling kidney cancer treatment results Tuesday, and shares rose, reversing a premarket dive. Continue Reading... Full story

Yahoo Finance • 2 months ago

Biotech Breakout: What's in focus after Moderna's cancer win?

[mRNA or messenger RNA. The concept of mRNA vaccine. Innovative methods to treat virus. 3d render] Krot Studio INVESTORS SHOULD KNOW: A major Phase 3 trial win from Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) and Merck (MRK [htt... Full story

Yahoo Finance • 6 months ago

How Eisai (TSE:4523) Is Reframing Its Story With A Tweaked Fair Value Outlook

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Eisai’s updated analyst model now points to a fair value price target of ¥5,076.92, compared with the prior ¥5,009.23, givi... Full story

Yahoo Finance • 6 months ago

Damora Therapeutics (DMRA) Appoints Jennifer Jarrett as President, Chief Executive Officer

Damora Therapeutics Inc. (NASDAQ:DMRA) is one of the best performing NASDAQ stocks according to Wall Street analysts. On March 23, Damora Therapeutics appointed Jennifer Jarrett as President and Chief Executive Officer, effective March 30.... Full story

Yahoo Finance • 6 months ago

Gilead’s Arcus Pullback and Idvynso HIV Challenge Might Change The Case For Investing In GILD

In April 2026, Arcus Biosciences said Gilead Sciences chose not to make a continuation payment, ending option rights to several early-stage Arcus programs while keeping time-limited options on select assets like AB801, AB598, AB102 and a T... Full story

Yahoo Finance • 7 months ago

5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up

Quick Read Incyte (INCY) posted FY2025 revenue of $5.14B (+21.2% YoY) with 14 pivotal trials underway across KRASG12D and CDK2 inhibition, while Alnylam (ALNY) achieved first full-year GAAP profitability with FY2025 revenue surging 65.2%... Full story

Yahoo Finance • 8 months ago

Arcus Biosciences Q4 Earnings Call Highlights

Arcus Biosciences logo Key Points Updated ARC-20 single-agent data show casdatifan (100 mg QD) with a confirmed ORR rising to 45% and median PFS of 15.1 months, which Arcus says compares favorably to belzutifan in late-line ccRCC. Phase... Full story

Yahoo Finance • 9 months ago

Here’s What Analysts Think About Arcus Biosciences (RCUS)

Arcus Biosciences, Inc. (NYSE:RCUS) is one of the best immunotherapy stocks to buy according to hedge funds. On February 12, Arcus Biosciences, Inc. (NYSE:RCUS) was downgraded to Equal Weight from Overweight at Wells Fargo, with the firm b... Full story

Yahoo Finance • 9 months ago

GILD's Q4 Earnings Beat Estimates, HIV and Liver Disease Drugs Power Sales

Gilead Sciences, Inc. GILD reported fourth-quarter 2025 adjusted earnings per share (EPS) of $1.86, which beat the Zacks Consensus Estimate of $1.83. The bottom line was down from $1.90 reported a year ago. The year-over-year decrease was... Full story

Yahoo Finance • 10 months ago

Here are the most and least likely M&A targets in biotech, according to Truist

[M&A - concept waiting for mergers and acquisitions.3D rendering on yellow background.] French biotech (ABVX [https://seekingalpha.com/symbol/ABVX]) has emerged as the most likely acquisition target among biotechs in 2026, significantly o... Full story

Yahoo Finance • 11 months ago

Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare Conference

HAYWARD, Calif., December 18, 2025--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, infla... Full story

Yahoo Finance • 11 months ago

Why Arcus Biosciences Just Reversed Its 287% Eight-Month Winning Streak

Arcus Biosciences stock plunged Friday, reversing a nearly 300% gain, after its Gilead Sciences-partnered cancer regimen failed. Continue Reading... Full story

Yahoo Finance • last year

Arcus Biosciences prices $250M offering

* Clinical-stage, global biopharmaceutical company Arcus Biosciences (RCUS [https://seekingalpha.com/symbol/RCUS]) priced [https://seekingalpha.com/pr/20287758-arcus-biosciences-announces-pricing-of-250-million-public-offering-of-common-... Full story

Yahoo Finance • last year

Sector Update: Health Care Stocks Advance Monday Afternoon

Health care stocks rose Monday afternoon, with the NYSE Health Care Index and the Health Care Select PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • last year

Stocks making the biggest moves midday: Broadcom, Bloom Energy, Critical Metals, Fastenal and more

Check out some of the companies making the biggest moves midday: Broadcom -- The chipmaker jumped 10% after agreeing with OpenAI to jointly build and deploy custom artificial intelligence accelerators , the first public plan released by th... Full story

Yahoo Finance • last year

Arcus Biosciences rises on results from domvanalimab cancer study

[Cancer Anatomy] wildpixel/iStock via Getty Images * Arcus Biosciences (NYSE:RCUS [https://seekingalpha.com/symbol/RCUS]) rose after it reported results from mid-stage study of its monoclinical antibody domvanalimab with zimberelimab an... Full story